C12N 2310/33
Of the base
Official title: of the base
C12N2310/33 (Of the base) appears on 1,876 US grants and 3,458 published applications in this corpus.
Search patents in C12N- Granted patents
- 1,876
- Published applications
- 3,458
- Assignees
- 638
- Inventors
- 3,189
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 2 | 0 |
| 1994 | 4 | 0 |
| 1995 | 4 | 0 |
| 1996 | 15 | 0 |
| 1997 | 29 | 0 |
| 1998 | 28 | 0 |
| 1999 | 52 | 0 |
| 2000 | 85 | 0 |
| 2001 | 77 | 12 |
| 2002 | 81 | 44 |
| 2003 | 41 | 231 |
| 2004 | 27 | 258 |
| 2005 | 20 | 174 |
| 2006 | 21 | 67 |
| 2007 | 17 | 64 |
| 2008 | 23 | 49 |
| 2009 | 33 | 100 |
| 2010 | 60 | 92 |
| 2011 | 52 | 91 |
| 2012 | 69 | 85 |
| 2013 | 55 | 98 |
| 2014 | 80 | 105 |
| 2015 | 84 | 148 |
| 2016 | 86 | 143 |
| 2017 | 76 | 123 |
| 2018 | 71 | 161 |
| 2019 | 112 | 161 |
| 2020 | 101 | 169 |
| 2021 | 107 | 177 |
| 2022 | 82 | 177 |
| 2023 | 71 | 186 |
| 2024 | 83 | 193 |
| 2025 | 76 | 201 |
| 2026 | 52 | 149 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2310/334Modified cIndexing code1,156
- C12N 2310/335Modified t or uIndexing code355
- C12N 2310/336Modified gIndexing code213
- C12N 2310/332Abasic residueIndexing code199
- C12N 2310/333Modified aIndexing code189
- C12N 2310/331Universal or degenerate baseIndexing code81
- C12N 2310/337In alpha-anomeric formIndexing code5
Recent patents
- MRNA 5′-end cap analogs modified within phosphate residues, RNA molecule incorporating the same, uses thereof and method of synthesizing RNA molecule or peptide29 Sep 2026US 12,747,261 B2Explorna Therapeutics Sp. z o.o.
- Compounds and methods for reducing PLN expression22 Sep 2026US 12,742,170 B2Ionis Pharmaceuticals, Inc.
- Compounds and methods for reducing FUS expression15 Sep 2026US 12,735,700 B2Ionis Pharmaceuticals, Inc.
- Oligonucleotide compositions and methods of use thereof15 Sep 2026US 12,735,703 B2Wave Life Sciences Ltd.
- RNAi agents and compositions for inhibiting expression of angiopoietin-like 3 (ANGPTL3), and methods of use8 Sep 2026US 12,729,377 B2Arrowhead Pharmaceuticals, Inc.
- Methods of treatment of chronic kidney disease8 Oct 2026US 2026/0308590 A1AstraZeneca AB
- Antisense oligomer formulations8 Oct 2026US 2026/0308595 A1Stoke Therapeutics, Inc.
- Rna preparations comprising purified modified rna for reprogramming cells1 Oct 2026US 2026/0297538 A1The Trustees of the University of Pennsylvania
- Trem compositions and methods of use1 Oct 2026US 2026/0297575 A1Flagship Pioneering Innovations VI, LLC
- Oligonucleotides comprising segmented gap structures1 Oct 2026US 2026/0297584 A1Ausperbio Therapeutics Inc.
Most cited
By later US patents
- N-2 substituted purines806US 5,459,255 AIsis Pharmaceuticals, Inc. · 1995
- Inhibitors for replication of retroviruses and for the expression of oncogene products698US 5,264,423 AThe United States of America as represented by the Department of Health and Human Services · 1993
- Sugar modified oligonucleotides that detect and modulate gene expression641US 5,670,633 AIsis Pharmaceuticals, Inc. · 1997
- Oligonucleotides having phosphorothioate linkages of high chiral purity626US 5,587,361 AIsis Pharmaceuticals, Inc. · 1996
- Oligonucleotides containing N-2 substituted purines621US 5,587,469 AIsis Pharmaceuticals, Inc. · 1996